Wrap Text
Acquisition of 100% of Cipla Agrimed Proprietary Limited and Cipla Vet Proprietary Limited
ASCENDIS HEALTH LIMITED
(Incorporated in the Republic of South Africa)
(Registration number 2008/005856/06)
ISIN: ZAE000185005 JSE share code: ASC
(“Ascendis” or “the Company”)
ACQUISITION OF 100% OF CIPLA AGRIMED PROPRIETARY LIMITED AND CIPLA VET
PROPRIETARY LIMITED
1. Introduction
Ascendis shareholders (“Shareholders”) are advised that the Company has entered into an
agreement on 4 March 2017 in terms of which Ascendis will acquire, directly or indirectly, the
entire issued share capital of Cipla Agrimed Proprietary Limited (“Cipla Agrimed”) and the
entire issued share capital of Cipla Vet Proprietary Limited (“Cipla Vet”) for a consideration of
R375 million (with a potential adjustment to reflect a price band of R250 million and R500
million in relation to actual working capital, net debt and earnings before interest, tax,
depreciation and amortisation (“EBITDA”) achieved for the period ending 31 March 2017 as
set out in paragraph 3 below) (the “Purchase Consideration”), from Inyanga Trading 386
Proprietary Limited, a fully owned subsidiary of Cipla Limited India (“Cipla”) (the “Proposed
Transaction”).
Cipla Vet and Cipla Agrimed are collectively referred to as the “Acquisitions” for the purposes
of this announcement.
The Acquisitions comprise the South African veterinary operations of Cipla, with operations as
follows:
- Cipla Vet operates in the companion animal segment with sales to over 1,000 outlets
via veterinary practices, veterinary shops, equine outlets and wholesalers. Cipla Vet
has a strong presence in the South African market in antibiotics, endoparasitcides and
ectoparasiticides, with leading positions in proton pump inhibitors, non-steroidal anti-
inflammatory drugs (NSAIDs) and supplements. Cipla Vet focuses on niche areas to
launch unique & differentiated products and has an attractive basket of registered
scheduled medicines with over 45 SKUs and 75 approved marketing authorisations.
Key brands include Triworm and Petcam.
- Cipla Agrimed operates in the commercial animals segment and sells unique
Ivermectin, Doramectin and Moxidectin combinations with vitamins and minerals. It
has a leading position in antimicrobials and endectocides in South Africa, as well as a
growing presence in endoparasiticides and ectoparasiticides. The entity furthermore
exports into sub-Saharan Africa, particularly to Namibia, Botswana, Zambia and
Angola.
2. Strategic rationale
Ascendis’ strategy is to create a synergistic group of health product brands that cover the value
chain from imports of raw materials, manufacturing and distribution to consumers via retail and
direct selling channels, spanning across human, plant and animal health.
The Acquisitions are an excellent strategic fit for the Phyto-Vet division of Ascendis as it offers
a presence in therapeutic areas in which Ascendis did not previously have strong
representation. Phyto-Vet is an integrated biosciences and veterinary science business,
leveraging expertise in the areas of entomology, horticulture, agronomy and veterinary
sciences to drive competitive advantage. Products are sold through veterinary practices,
veterinary shops, equine outlets, wholesalers, distributors, independent retailers, dealers and
co-operatives.
Key features of the Proposed Transaction include:
- Expansion into the veterinary pharma industry complements Ascendis’ existing presence
in the pharma industry and Phyto-Vet’s existing Sub-Saharan African biosciences
business;
- Phyto-Vet has plans to increase international revenue by opening new markets in Sub-
Saharan Africa, supported by the Acquisitions’ existing presence and Ascendis’ existing
distribution network;
- Strategic touch points with major players in the agricultural and animal health sectors
through Phyto-Vet’s involvement in agri-chemicals;
- Phyto-Vet has an ongoing programme of basic and applied research to develop new
products and processes, to improve and refine existing products and processes, and to
develop new applications for existing products, which would support the future pipeline of
the Acquisitions.
3. Salient terms of the Proposed Transaction
The Purchase Consideration of between R250 million and R500 million will be settled out of
existing cash and facilities as follows:
3.1 R325 million, plus interest accrued from the Effective Date to the closing date, which
will be settled in cash by transfer to a Cipla designated bank account on closing,(“Day
1 Payment”);
3.2 A potential purchase price adjustment which will be settled approximately 2 months
post closing and which will adjust the Day 1 Payment to reflect an amount between
R200m and R450m based on the following:
3.2.1 A 7.5x EBITDA multiple will be applied to a maximum variance of up to R5
million in actual EBITDA achieved for the period ending 31 March 2017 versus
the target EBITDA, resulting in a maximum increase or decrease in the Day 1
Payment of R37.5m; and
3.2.2 Actual working capital and net debt versus the target working capital and net
debt may result in a maximum of the balancing variance in the Day 1 Payment;
and
3.3 A deferred payment of R50 million which will be settled in cash on 2 July 2018.
At the date of this announcement the only outstanding significant condition precedent is the
approval of the South African competition authorities.
The effective date for the Proposed Transaction is expected to be 1 April 2017 (“Effective
Date”).
4. Financial Information
The combined profit after tax of the Acquisitions was R31 million for the period ended 31 March
2016 and the combined net asset value of the Acquisitions was R138.3 million as at 31 March
2016.
5. Categorisation of the Proposed Transaction
The Proposed Transaction is categorised as a Category 2 transaction in terms of the JSE
Limited Listings Requirements.
06 March 2017
Johannesburg
Arranger and Financial Advisor
Coast2Coast Capital Proprietary Limited
Sponsor
Investec Bank Limited
Date: 06/03/2017 07:05:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.